Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of ABSK061 + ABSK043 with or without chemotherapy in FGFR2/3-altered metastatic or unresectable solid tumors
CTR20243834Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lavengratinib, lumipodlin in Nonhematologic neoplasms, gastric cancer (GC), esophagogastric junction cancer, transitional cell carcinoma (TCC), non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Started Nov 2024; status: active.
02
Drugs
lavengratiniblumipodlin
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)esophagogastric junction cancertransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243834.